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Abstract
Immunotherapy has struggled to reduce the high mortality rate of pancreatic cancer,
in part due to the low mutation burden and immunosuppressive microenvironment
associated with the disease. Early successes have been limited to a small number
of patients, highlighting the difficulty of attempts to modulate immune systems that
have evolved to be unique in each patient.
To better understand the mechanisms of anti-tumor immune responses and elu-
cidate the differences between clinical responders and non-responders, an analysis
of T-cell receptor repertoires of 106 pancreatic cancer immunotherapy patients was
performed using a newly developed analysis package, immunoSeqR. The data provides
new insights into the effects of several immunotherapies used in current clinical trials,
including immune checkpoint blockade. Additionally, diverse baseline repertoires and
treatment induced clonal expansion were found to be significantly associated with
clinical response.
Cancer vaccines must provide a source of antigens to direct an immune response,
and while neoantigens arising from point mutations are often utilized for this pur-
pose, fusion antigens, derived from genomic rearrangements are frequently overlooked.
Seventeen putative fusion neoantigens were identified in two pre-clinical models and
tested for their ability to induce immune responses and protect against tumor chal-
lenge when administered as a peptide vaccine. Antigen identification from next gen-
eration sequencing data was identified as a critical bottleneck for the development of
personalized fusion vaccines.
ii
Analysis of the T-cell receptor repertoire in clinical trial patients provides new in-
sights into the effects that vaccines, radiation, chemotherapy and checkpoint blockade
have on the complex lymphocyte compartment. Current vaccine approaches typically
proceed without knowledge of whether antigens included in the vaccine are shared
by the patient. Personalized vaccine approaches solve this problem, and advances
in technology are reducing the cost and time required for their development. To-
gether, these two approaches represent significant steps in closing the response gap
in pancreatic cancer immunotherapy.
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Pancreatic cancer consistently ranks among the most deadly cancer types. In the
next year, an estimated 53,000 people will be diagnosed in the United States, and
only around 7% will survive for 5 years1. Around 20% of cases are attributed to
smoking, and around 10% of patients have a family history of the disease2. By far
the most abundant subtype is pancreatic adenocarcinoma, which typically arises in
the epithelial cells of the pancreatic ducts.
Ideally, treatment begins with surgery, however 80% of patients have unresectable
disease at diagnosis3. Fluorouracil or gemcitabine based chemotherapy and radia-
tion remain the front-line therapy, however, a wide variety of immunotherapies are
emerging as promising new treatment avenues.
1.2 Cancer Immunotherapy
The first recorded use of a therapy which harnessed the immune system to combat
tumors was in 1891, when a physician in New York injected bacteria into tumors after
noticing spontaneous remissions in sarcoma patients with concurrent infections. A
century later, researchers demonstrated that cytotoxic T-lymphocyte associated pro-
tein 4 (CTLA4), expressed on the surface of T-cells, acts to prevent T-cell activation
1
by antigen presenting cells4. Shortly thereafter, the same group demonstrated that
inhibition of this molecule using a therapeutic antibody allows the immune system to
target tumor cells in mice5. This observation was quickly confirmed in humans when
anti-CTLA4 became the first therapy to extend the lifespan of advanced melanoma
patients6. This re-discovery of the possibilities of cancer immunotherapy ignited the
current field of research, which has further explored the potential of antibodies target-
ing immune checkpoint inhibitors, returned to the century old method of intratumoral
injection of bacteria, and branched into countless other areas of investigation.
One such branch of investigation includes cancer vaccines, which can either be
developed for prevention or treatment of existing cancers. Allogeneic pancreatic
cancer vaccines, genetically engineered to secrete granulocyte macrophage colony-
stimulating factor (GM-CSF), termed GVAX, were first introduced as a potential
pancreatic cancer therapy in 20017. Phase I trials showed promising immune in-
filtration, and Phase II trials indicated a slight clinical benefit when compared to
chemotherapy8. Like GVAX monotherapy, trials of anti-CTLA4 alone in PDA were
underwhelming9, which is why current clinical trials pair the vaccine with the check-
point inhibitors anti-CTLA410 and anti-PD111, as well as genetically modified, tumor
antigen-expressing Listeria monocytogenes12. The goal of these combinations is to si-
multaneously provide a broad range of potential tumor-specific antigens and remove
the barriers to T cell activation in the periphery (with anti-CTLA4) or the tumor
(with anti-PD1).
Clinically, GVAX is administered as a mixture of two human pancreatic cancer
cell lines, modified to secrete GM-CSF. Because it is allogeneic, altered peptides
resulting from patient-specific mutations (neoantigens) are unable to be targeted, and
immunogenicity is contingent on common mutations that occur in the cell lines and
the patient’s tumor (cancer antigens). A variety of novel approaches are attempting
truly personalized cancer vaccines, in which each patient’s tumor DNA is sequenced
2
and potential neoantigens are identified, synthesized, and administered to the patients
as a therapeutic vaccine via a number of possible methods. This method has the
potential to target as many good quality tumor antigens as possible, but is often
prohibitively expensive and frequently requires more time to develop than is possible
for patients with advanced disease.
1.3 Immune Repertoire Profiling
Historically, descriptions of a patient’s immune health relied on laborious and rela-
tively unsophisticated laboratory methods, including blood counts. While clinically
instrumental in a number of disease cases, these methods fail to identify subtle changes
in the population of immune cells which may be earlier and more accurate markers
of disease. Researchers interested in examining the repertoire of B or T lympho-
cytes had a limited set of tools available. Typically, staining of T lymphocytes with
fluorescent labeled multimers of major histocompatibility complex (MHC) molecules
provided the broadest possible look at the repertoire, but this powerful method suffers
from several key limitations. First, T-cells see their cognate antigen in the context of
specific MHC molecules. In the population, hundreds of MHC allele variants exist,
and in an individual, several different alleles can be expressed. This allele restriction
problem means that MHC multimer staining can only look at one allele at a time.
Additionally, antigenic peptides must be known a priori in order to be tested in this
assay, so screening efforts of large libraries are necessary to identify novel antigens.
A complementary approach involves amplification of specific genomic rearrange-
ments associated with lymphocyte development. Somatic recombination is a unique
feature of the adaptive immune system which involves the removal and rearrange-
ment of individual gene segments inside each lymphocyte, followed by the insertion
of random non-templated nucleotides. The result of this process is that each newly
generated immune cell contains a unique receptor with complementary determining
3
regions (CDRs) created by both the combinatorial mechanism (three gene segments
V, D and J are combined, each drawn from a large pool of possible locii), and random
addition and deletion of nucleotides. The human body contains around 25-100 million
unique T-cell clones, comprising an estimated 1012 total T-cells13, but the process of
VDJ recombination allows for an estimated 1016 possible unique T-cell receptors14.
While PCR amplification of the CDR regions has been possible for decades, it took
the development of modern parallel sequencing technologies for the quantification of
the repertoire to become possible.
The foundations for the current technology were laid in 2009, when it was demon-
strated that sequencing of the CDR3 region of the TCRβ chain allowed rapid quan-
tification of the TCR repertoire and tracking of individual clones over time14. The
throughput of this assay, as well as its depth make it a powerful tool for immune mon-
itoring, however there are notable drawbacks. First, unlike MHC multimer staining,
high throughput T-cell receptor Vβ sequencing (HTTCS) does not allow identifi-
cation of the cognate antigen associated with each sequence. In fact, because the
technology sequences only the β chain, and peptide recognition requires both the α
and β chains, antigen identification directly from this data is impossible. Second, the
technology can not itself distinguish between T-cell subtypes, whereas this would be
easily accomplished in MHC multimer staining using multi-channel flow cytometry.
The result is that if the subset population (i.e. CD4+ vs CD8+ ) is of interest, the
populations must be separated and run as separate samples in the HTTCS assay.
Despite these challenges, this technology found early use as a clinical assay to
monitor response to therapy in patients with lymphoblastic leukemia15. It was quickly
adopted for research into infectious diseases16 and eventually cancer immunotherapy,
where current efforts focus on determining the mechanisms of new therapies, and
predicting clinical responses by monitoring immune health.
4
Chapter 2




2.1.1 T Cell Receptor Profiling
The development of high throughput T cell receptor Vβ sequencing (HTTCS) has
allowed the identification and temporal monitoring of clones with much greater sensi-
tivity than previous methods. The technology uses a pool of 45 primers specific to all
known variants of the V segment of the TCRβ gene, as well as 13 primers specific to
known Jβ regions to amplify all rearranged TCR sequences in a given DNA sample.
After amplification, the product is sequenced using Illumina sequencing technologies,
and unique TCR sequences can be counted. The quantities of each primer are cali-
brated to normalize any variation in amplification efficiencies, and a computational
method using control samples is used to further reduce noise. The resulting data set
contains the nucleotide sequences of each unique T-cell receptor identified, along with
an estimation of how many copies of that sequence were present in the sample.
Initial applications of this technology focused on quantifying minimal residual
disease in patients with hematopoietic malignancies, in which a single malignant
clone is tracked during the course of therapy17. It was quickly recognized, however,
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that descriptions of the repertoire provided information about the overall health of
the immune system.
HTTCS was used, for example, in immunotherapy trials in melanoma, where it re-
vealed that inhibition of CTLA4 leads to an expansion of the T cell repertoire. This
expansion was also correlated with increased toxicity18. Several additional groups
have now correlated TCR repertoire metrics with various measures of clinical out-
come19,20,21, though the methods used vary widely between studies.
TCR repertoire studies of patients treated with anti-PD1 have focused primarily
on the tumor repertoire, rather than the peripheral repertoire, due to the fact that
anti-PD1 acts upon previously activated T-cells at the site of the tumor. Differ-
ences in peripheral repertoire metrics in patients treated with either anti-CLTA4 or
anti-PD1 have been described22, hinting that peripheral diversity is less important
in the case of anti-PD1 treatment. Repertoire profiling in the tumor creates unique
challenges for the technology and analysis. Formalin fixed, paraformaldehyde embed-
ded tissues, for example, experience DNA degradation, resulting in poor sequencing
quality. Additionally, low numbers of T-cells present in the sample (compared with
peripheral blood) lead to estimates of diversity which do not accurately represent the
larger population. Finally, T-cells do not distribute themselves randomly inside a
tumor, but rather assemble into complex structures known as tertiary lymphoid ag-
gregates23. Because of this non-random spatial distribution, the number and makeup
of T-cells can vary greatly between slides cut from the same tumor block. Conflicting
studies have been published showing a high degree of concordance between multiple
samples taken from the same tumor in ovarian cancer24 and very low concordance be-
tween multiple samples of the same renal cell carcinoma25. Despite these challenges,
in at least one study, clinical responders have been shown to have a greater number
of expanded clones, as well as increased repertoire clonality among tumor infiltrating
lymphocytes26.
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One of the hallmarks of cancer immunotherapy has been surprising clinical re-
sponses in a subset of patients. Predicting which patients will respond to certain
therapies has been elusive, due to the complexity of the immune response. HTTCS
measures this complexity to an unprecedented degree, leading a number of groups to
pursue repertoire metrics as possible biomarkers for immunotherapy. In metastatic
breast cancer, for example, it has been demonstrated that a model using lymphopenia
combined with repertoire diversity is predictive of clinical outcome20. Larger studies
will be necessary to provide sufficiently large test datasets to determine the efficacy of
these biomarkers, but HTTCS seems like a promising technology for this application.
In the present study, HTTCS is used to examine 343 peripheral and tumor TCR
repertoires taken from 106 pancreatic cancer patients enrolled in 5 clinical trials of
different immunotherapies. To analyze this number of TCR repertoire samples, an R
package called immunoSeqR was developed, allowing efficient processing of count data
and management of sample metadata. The results indicate that repertoire clonality
and the number of expanded clones are both associated with clinical outcomes, but
only in some therapeutic contexts.
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2.1.2 Clinical Trials
Adjuvant and Neoadjuvant GVAX
Details of the J9988 clinical trial (NCT00084383, herein the Adjuvant trial) have
been described previously8. Patients eligible for this trial had histologically diagnosed
pancreatic adenocarcinoma which was successfully removed (R0 or R1) by surgical
resection within 10 weeks of enrollment. Patients were excluded for a variety of crite-
ria, including metastatic disease, autoimmune or allergic disease, recent corticosteroid
use, and HIV infection.
Enrolled patients were given the first dose of GVAX (5×108 total cells) 8-10 weeks
following surgery. Around 2 weeks after vaccination, patients received 5-fluorouracil
and radiation therapy. Following chemoradiation, patients received up to 3 mainte-
nance doses of GVAX at 4 week intervals, and additional boosts 6 months following







































































Figure 2.1: Timeline of the Adjuvant (top) and Neoad-
juvant (bottom) GVAX studies. Black arrows indicate
treatments and red arrows indicate blood draws taken
during the study.
The neoadjuvant GVAX (J0810, NCT00727441) trial enrolled patients with re-
sectable pancreatic adenocarcinoma, with no detectable metastasis23. Patients treated
within 28 days with any anti-cancer therapy, steroid or immunosuppressive therapy,
as well as patients previously treated with immunotherapy at any time were excluded
from this study.
Patients enrolled in this trial were administered GVAX (alone or in combination
with either oral or intravenous cyclophosphamide) two weeks before surgical resection.
Following surgery, patients were treated with standard chemotherapy and radiation,
followed by additional doses of GVAX every four weeks (see Figure 2.1, bottom).
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Stereotactic Body Radiation with GVAX
Patients were enrolled in the J1179 (NCT01595321) clinical trial with documented
pancreatic cancer within 10 weeks of successful surgical resection. Patients were
excluded if they were given any prior therapy for pancreatic cancer, had metastatic
disease, or any autoimmune or allergic disease.
Enrolled patients in arm 2 were treated with cyclophosphamide and GVAX two
weeks before undergoing Stereotactic Body Radiation Therapy (SBRT). All patients
(in arms 1 and 2) received SBRT, and 6 cycles of chemotherapy (FOLFIRINOX).
Following chemotherapy, patients in arm 2 received additional maintenance doses of






























Figure 2.2: Timeline of the SBRT GVAX study. Black
arrows indicate treatments, red arrows indicate blood
draws taken during the study. All patients received treat-
ments listed in black, and one arm received additional
treatments listed in blue.
Anti-CTLA4 or anti-PD1 with GVAX
In the J0834 clinical trial (NCT00836407), patients were enrolled with local, advanced
or metastatic pancreatic adenocarcinoma, previously treated with gemcitabine-based
chemotherapy. Patients treated with anti-CTLA4 at any time, or any other cancer
therapy within 28 days were excluded, as were patients with brain metastases or
infection with HIV or hepatitis B or C.
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Enrolled patients received 10mg/kg Ipilimumab only (arm 1) or 10mg/kg Ipili-
mumab + GVAX (arm 2) every three weeks for four cycles, followed by maintenance
dosing (see Figure 2.3, top).
The J14113 clinical trial (NCT02243371) enrolled patients with metastatic pancre-
atic adenocarcinoma who failed one previous therapy for metastatic disease. Patients
treated previously with anti-PD1, anti-PDL1/2, anti-CTLA4, GVAX, CRS-207 at
any time or patients treated with steroids or immunosupressants within 28 days were
excluded, as well as patients with HIV, hepatitis B or C infections.
Once enrolled, patients received two doses of GVAX followed by four doses of
CRS-207, a strain of Listeria monocytogenes expressing mesothelin, a tumor antigen
expressed by many tumors. Patients in arm 1 of this study were also administered
3mg/kg Nivolumab with all treatments (see Figure 2.3, bottom).
For both studies, baseline samples collected before the initial treatment (PRE) as
well as after the third cycle (POST3) were used for analysis.
11

































































































































Figure 2.3: Timeline of the J0834 (top) and J14113 (bot-
tom) clinical trials. Black arrows indicate treatments.
Red arrows indicate blood draws used in this study.
Black text indicates treatments received by patients in
both arms, blue text indicates only patients in combina-
tion arm. LM: Listeria monocytogenes
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2.2 Materials and Methods
2.2.1 Development of the immunoSeqR R Package
The immunoSeqR package for the R programming language was created to analyze
data from large HTTCS experiments and organize experiment level metadata. The
analysis of TCR data using this package involves the following steps:
1. Importing data from raw .tsv files
2. Merging samples together based on matching TCR sequences
3. Aggregating synonymous DNA sequences into single amino acid sequences
4. Calculating sample level and patient level statistics
5. Building a metadata dictionary
6. Graphical representation of data
The data is imported into a single data.frame containing all of the samples. Rows
represent unique T cell clones and columns represent samples. When clones are not
shared between samples, the table is completed by adding zeros. This results in a
larger than necessary table, but saves time by not having to join samples at the time
of analysis.
Samples are merged using the iseqr_merge() function:
all_files <- list.files("/path/to/tsv",pattern=".tsv")
# construct the dataset with iseqr_merge
ds <- iseqr_merge(all_files)
When sequencing from peripheral tissues, the data may contain TCRs with non-
productive rearrangements, or stop codons within the CDR3 region. These are filtered
out before proceeding.
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Multiple synonymous nucleotide sequences can encode the same CDR3 amino
acid sequence, so after the data has been joined, it must be aggregated, by sum-
ming the counts from synonymous sequences together. This is accomplished with the
iseqr_aggregate() function:
ds_agg <- iseqr_aggregate(ds,inc_nt=FALSE)
which produces a data set containing individual unique CDR3 sequences in rows,
and samples in columns. Summary statistics, including Richness and Clonality (dis-
cussed in Chapter 2.2.2) are calculated using the aggregated data, while expanded
clones are calculated from the nucleotide level data.
Summary statistics can be calculated easily with the data in this format using the
apply() family of functions. Clonality for example, can be easily calculated for all
samples at once using
sapply(ds_agg,clonality)
Once the dataset is created, a metadata dictionary is created. This object is a
data.frame in which each row corresponds to a column in the data set, and thus
to a sample. The dictionary contains information about the sample such as which
patient it was collected from, and at what time point. It also contains demographic
information about each patient, including their age, sex, clinical response, Response
Evaluation Criteria In Solid Tumors (RECIST) status, adverse event status, etc. After
the metadata is collected, other statistics can be calculated, including the change
in each metric before and after treatment, as well as the overlap between relevant
samples. Finally, the dictionary and summary statistics are combined into a single
data.frame (a plot_ds object), where each row contains the metadata and summary
statistics for each sample.
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The dictionary also enables the immunoSeqR package to more easily create plots
with relevant layouts. By supplying the function iseqr_plot_factor() with the
plot_ds object, a metric to plot, and a metadata field to compare, a plot (Figure
2.4) is created using the ggplot package, including 95% confidence intervals for the








































Figure 2.4: An example plot created with the
iseqr_plot_factor() function. The metadata and
summary statistics are stored in the plot_ds object, al-
lowing the function to divide the data, calculate the 95%
confidence interval (red bars) and plot the data.
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2.2.2 Statistical Methods
Sample clonality is based on the normalized Shannon Entropy27, and is computed as





where pi is the proportion of the ith clone, in a population with n clones. For
paired pre and post-treatment samples, the normalized change in clonality was cal-
culated as the base 2 logarithm of the ratio of the post-treatment clonality to the
pre-treatment clonality.






where Dx represents the Simpson’s Index (given below in equation 2.3) of sample
x, nx represents the Richness of sample x, and xi represents the abundance of the ith





A Fisher Exact test was used to identify significantly expanded clones between
pre and post treatment samples16. For each clone, the pre and post treatment counts
are placed in the top row of a 2 × 2 contingency table, and the number of total T
cells for each sample is placed in the bottom row. A one-sided Fisher’s Exact Test is
used to assign a p-value to each table, and thus each clone. To correct for multiple
comparisons, the Benjamani & Hochberg Procedure28 is used to maintain a False
Discovery Rate of α = 0.05. The number of significantly expanded clones for each
patient is then calculated as the total number of clones with p < 0.05 after multiple
comparison correction.
16
All metrics were compared across binary categorical sample groups using a non-
parametric Wilcox rank-sum test. In cases where more than two groups were com-
pared, an ANOVA was used to determine significance. For cases where metrics are
compared to continuous variables (such as dose), a Pearson coefficient was used to
assess the strength of correlation.
2.2.3 Preparation of Samples
Peripheral blood mononuclear cells (PBMC) were processed as previously described29
and in accordance with the standard operating procedures of each clinical trial, and
stored in liquid nitrogen until testing. PBMC samples were thawed, counted and
frozen as a cell pellet, assuring that, for each patient, the same number of cells was
sent for each time point. PBMC samples were sequenced using the immunoSeq assay14
at the deep sequencing level.
Tumor samples from surgical resections and needle biopsies were formalin fixed
and paraffin embedded in accordance with the standard operating procedures of the
clinical trials. Slides from each tissue section were stained with Hemotoxylin and
Eosin (H&E) and assessed for their tumor purity. For each patient, the tumor sections
with the highest tumor content were selected and any sections containing intestinal
tissue or other potentially confounding tissues were discarded. Ten 25µm sections
were cut from these tissue selections for sequencing. Tumor sequencing was performed
using the immunoSeq FFPE assay at the survey level.
17
2.3 Results
2.3.1 GVAX as Adjuvant and Neoadjuvant Therapy With
Chemotherapy
Patients enrolled were treated with GVAX before chemoradiation, but either after
(J9988, adjuvant) or before (J0810, neoadjuvant) surgical resection of the tumor (See
Figure 2.1). At baseline, patients receiving neoadjuvant GVAX had significantly more
clonal peripheral T cell repertoires than patients on the adjuvant trial, a trend which













































































Figure 2.5: The clonality of all patients before (left) and
after (right) treatment, separated by study.
To assess the effects of the different treatment modalities on individual patients,
the fold change in clonality relative to baseline (log2 normalized) was used. The ma-
18
jority of patients on the neoadjuvant trial developed more clonal repertoires following
treatment (increase in clonality, positive fold change) when compared to patients















































Figure 2.6: The Log2 normalized fold change in clonality
from pre to post treatment of all patients, separated by
study.
Patients treated in the neoadjuvant study experienced larger changes in their
repertoire following treatment, indicated by significantly lower Morisita indices (a
measure of similarity, Figure 2.8). No significant change between the trials was ob-





















































Figure 2.7: The number of significantly expanded clones



































Figure 2.8: The Morisita index (a measure of similarity)
of all patients separated by study
The relatively large variability of these metrics in the neoadjuvant study led to the
hypothesis that the administration of cyclophosphamide (and its method of adminis-
tration) may have a large effect on the T cell repertoire. To test this hypothesis, each
treatment arm (including the adjuvant study for comparison) was assessed separately,
using the same metrics as before. Significant group differences were identified using
ANOVA. The average baseline clonality was significantly different among groups, but







































































































































Figure 2.9: Pre-treatment (left) and post-treatment
(right) clonality of each sample, separated by treat-
ment arm. aGVAX represents adjuvant vaccination (vac-
cine is administered after surgery) and naGVAX repre-
sents neoadjuvant treatment (vaccine administered be-
fore surgery). P-values represent results of ANOVA anal-
ysis at each time point.
On a per patient basis, significant differences were observed between groups in the
fold change of clonality relative to baseline (Figure 2.10). Patients who received oral
or IV cyclophosphamide had larger increases in clonality following treatment than

















































Figure 2.10: The Log2 normalized fold change in clon-
ality from pre to post, separated by treatment arm. P-
values represent results of ANOVA analysis.
The overall change in the repertoires (quantified by the Morisita index) was un-






















































Figure 2.11: The number of significantly expanded clones
following treatment in all patients, separated by treat-




































Figure 2.12: The Morisita index (a measure of similar-
ity) of all patients of all patients separated by study, sep-
arated by treatment arm. P-values represent results of
ANOVA analysis.
To better understand the mechanisms of successful anti-tumor vaccination, and
to assess the possibility of HTTCS as a prognostic marker, patients were separated
by clinical response (responders defined as >6 months overall survival) and assessed
using the same series of metrics. In the adjuvant trial, clinical responders trended
towards more diverse repertoires (before and after treatment), however this difference
was not significant. No changes in clonality were observed in clinical responders in







































































Figure 2.13: The clonality of all patients in the neoad-
juvant (left column) and adjuvant (right column) before
(bottom row) and after (top row) treatment, separated
by clinical response (defined as at least 6 months overall
survival).
As observed in the aggregate data, no difference was observed in the patient level



















































Figure 2.14: The Log2 normalized fold change in clonal-
ity from pre to post treatment, of patients on the neoad-
juvant (left) or adjuvant (right) trials, separated by clin-
ical response.
Clinical responders were likewise indistinguishable from non-responders using the
Morisita index (Figure 2.16) or the number of expanded clones (Figure 2.15), though
a counterintuitive trend was observed in the latter, with clinical responders having a





















































Figure 2.15: The number of significantly expanded clones
after treatment in patients in the neoadjuvant (left) or



































Figure 2.16: The Morisita index of all patients in the
neoadjuvant (left) and adjuvant (right) trials, separated
by clinical response.
For a subset of patients on both trials, material from the surgical resection was
available for TCR repertoire analysis. Due to the comparatively low numbers of T-
cells present in the tumor, it was first necessary to assess the number of total TCRs
sequenced in each sample. The clonality metric is only a valid representation of the
repertoire in cases where the number of T-cells sequenced is greater than 100. In
tumor samples taken from patients in these studies, the vast majority were above this










































Figure 2.17: Total number of TCR sequences for tumor
samples from patients in the adjuvant and neoadjuvant
trials
No significant difference was observed between treatment arms (ANOVA, p =
0.43) or between clinical response groups in the clonality of tumor repertoires (Figure
2.18). Due to the lack of biopsy material available, pre and post-treatment compar-













































































Figure 2.18: The clonality of tumor sections in the adju-
vant and neoadjuvant trials, separated by treatment arm
(top) and clinical response (bottom).
31
2.3.2 GVAX with Stereotactic Body Radiation Therapy
Patients enrolled in the J1179 clinical trial received Stereotactic Body Radiation Ther-
apy (SBRT) after surgical resection, but before 6 courses of FOLFIRINOX chemother-
apy (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin). Patients in one arm also
received cyclophosphamide and GVAX before radiation.
To assess any effects of GVAX treatment on SBRT treated patients, the clonality
at each time point was compared between treatment arms. No significant differences
in clonality were observed between GVAX treated and untreated patients at any of


























































Figure 2.19: The clonality of all patients on the SBRT
study before treatment (left) after radiation (center) and
after chemotherapy (right), separated by treatment arm.
Comparing individual SBRT treated patients by fold change in clonality, no dif-
32
ferences were observed between treatment arms (Figure 2.20). Notably, all but three
patients in this trial experienced a net diversification of their repertoires, unlike pa-
tients treated in the neoadjuvant study, in which most patients’ repertoires became


















































Figure 2.20: The Log2 normalized fold change relative
to pre-treatment of all patients on the SBRT study, after
radiation (left) and after chemotherapy (right), separated
by treatment arm.
To assess if this decrease in clonality is consistent with T-cell death induced by
radiation, a computational simulation of T-cell death was developed in which a set
percentage of clones was randomly removed from the data and the clonality and
richness were recalculated. The process was repeated 10000 times to generate a dis-
tribution of simulated post-radiation repertoire metrics. A representative baseline
sample (with clonality 0.06, richness 158605) was selected, and 0.25%, 0.5% or 1% of
33
the clones were randomly chosen and deleted (this represented a loss of 675, 1350 and
2700 clones from the original 1.6×105, respectively). The distributions of the sim-
ulated post-radiation repertoires (Figure 2.21) demonstrated that deletion of clones
from the repertoire always results in reduced richness, by necessity, but more inter-
estingly it also always results in a decrease in clonality, with larger removals resulting
in larger diversifications. This counterintuitive property arises from the fact that the
majority of clones in a diverse sample are present at very small numbers, with a few
clones existing in large quantities. Random deletions, therefor preferentially affect
these clones with high abundance first. It is worth noting that the magnitude of the
change in clonality demonstrated by these simulations is very small in comparison to
changes seen in biological samples, indicating that massive loss of T-cells would be





















Figure 2.21: The distributions of richness (top) and clon-
ality (bottom) in simulated post-radiation repertoires in
which 1% (black), 0.5% (grey) or 0.25% (red) of clones
were randomly deleted, 10000 times each. The red lines
represent the richness or clonality of the pre-treatment
sample from which the simulations were created.
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Despite the changes observed in clonality, neither the number of expanded clones
(Figure 2.22), nor the Morisita index (Figure 2.23) were significantly different between





















































Figure 2.22: The number of significantly expanded clones
relative to pre-treatment for all patients in the SBRT
study, after radiation (left) and after chemotherapy








































Figure 2.23: The Morisita index comparing all patients
pre-treatment samples to time points after radiation
(left) and after chemotherapy (right), separated by treat-
ment arm.
To better understand the effects of targeted radiation on the peripheral immune
system, T cell repertoire metrics were correlated with the reported Planned Treatment
Volumes (PTV80) which measures the volume of tissue expected to receive significant
amounts of radiation during treatment. No significant correlations were observed






























































Figure 2.24: The clonality of all patients on the SBRT
study before treatment (left) after radiation (center) and
after chemotherapy (right), compared with the radiation
volume (PTV80).
Using the log2 fold change of clonality relative to baseline, a significant correla-
tion was observed after SBRT, with lower radiation volumes associated with greater
diversification of the repertoire (p = 0.0198). Interestingly, this trend was completely
reversed after treatment with FOLFIRINOX, although the negative correlation was




















































Figure 2.25: The Log2 normalized fold change in clon-
ality, relative to the pre-treatment time point after ra-
diation (left) and after chemotherapy (right), compared
with the radiation volume (PTV80).
No significant correlations were observed between radiation volume and either the
























































Figure 2.26: The number of significantly expanded clones
after radiation (left) and chemotherapy (right) for pa-









































Figure 2.27: The Morisita index showing the change in
the repertoire relative to pre-treatment, after radiation
(left) and after chemotherapy(right), compared with the
radiation volume (PTV80).
40
2.3.3 GVAX with Immune Checkpoint Inhibitors
Patients in the J0834 clinical trial received anti-CTLA4 with or without GVAX, while
patients in the J14113 trial received GVAX followed by CRS-207 with or without anti-
PD1.
To assess the baseline characteristics of patients in each treatment arm of these
studies, as well as to examine the overall effect of treatment, the clonality was com-
pared between treatment arms both before (Figure 2.28, left) and after (Figure 2.28,
right) treatment. At baseline, the average repertoire clonality was slightly lower (more
diverse) in patients enrolled on the anti-CTLA4 study, however this trend was not
significant. For all treatment arms, peripheral repertoires were slightly more diverse





















































































































































































Figure 2.28: The clonality of all patients at baseline
(left) and after 3 cycles of treatment (right), separated
by treatment arm.
To examine the effect of treatment on individual patients, the log2 fold change in
41
clonality was compared between all treatment arms (Figure 2.29). The majority of
patients experienced a net diversification of their peripheral repertoires. A greater




























































































Figure 2.29: The Log2 normalized fold change in clon-
ality relative to baseline for each patient on the anti-
CTLA4 and anti-PD1 trials, separated by treatment arm.
No significant difference was observed in the number of expanded clones between
treatment arms (Figure 2.30), however patients receiving anti-CTLA4 with GVAX
had significantly larger changes in their repertoires than patients receiving anti-PD1

































































Figure 2.30: The number of expanded clones following
treatment for all patients on the anti-CTLA4 and anti-
PD1 trials, separated by treatment arm.
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Figure 2.31: The Morisita index of all patients, sep-
arated by treatment arm (left). Representative scat-
ter plots showing each clone before and after treatment
for patients with high (top right) or low (bottom right)
Morisita index. Arrows indicate which repertoires are
shown at right.
Finally, to assess the ability of TCR repertoire metrics to differentiate clinical
responders, each metric was used to compare patients with overall survival of > 6
months (R) or < 6 months (NR). At baseline, anti-CTLA4 treated patients with
44
longer overall survival had more diverse peripheral TCR repertoires (Figure 2.32).
This trend was completely absent in patients in the anti-PD1 trial. Interestingly, the
trend was no longer observed after treatment (Figure 2.32), possibly because most














































































































































































anti−PD1 + GVAX + LM
GVAX + LM
Figure 2.32: The clonality of each patient before (left)
and after (right) treatment. Samples are separated by
clinical response and trial, and colored by treatment
arms.
Because of the striking difference in baseline repertoire clonality, the log2 fold
change in clonality is more difficult to interpret. No significant differences were
observed between responders and non-responders in either study using this metric
(Figure 2.33). Non-responders seem to have slightly more diversification than clinical
responders, however this is likely the result of extremely low baseline clonality in


































































































anti−PD1 + GVAX + LM
GVAX + LM
Figure 2.33: The log2 normalized fold change in clonality
of all patients on the anti-CTLA4 and anti-PD1 trials,
separated by trial and clinical response, and colored by
treatment arm.
Clinical responders treated in the anti-CTLA4 study experienced dramatically
more expanded clones following treatment (Figure 2.34), with mean 225.5 expanded
clones in responders, compared with 33.8 in non-responders. As seen previously with
clonality, the trend was not observed in patients receiving anti-PD1, where clinical










































































anti−PD1 + GVAX + LM
GVAX + LM
Figure 2.34: The number of expanded clones following
treatment in patients enrolled in the anti-CTLA4 and
anti-PD1 trials, separated by clinical response and trial,
and colored by treatment arm.
The Morisita index was largely unchanged between clinical responders and non-
responders in both studies, with patients in the anti-CTLA4 study showing a trend
towards more change in patients with longer survival. None of the changes observed
























































































anti−PD1 + GVAX + LM
GVAX + LM
Figure 2.35: The Morisita index of all patients on the
anti-CTLA4 and anti-PD1 trials, separated by clinical
response and trial, and colored by treatment arm.
Because of the striking association between clinical outcome and both diverse
baseline repertoires and high number of expanded clones, both were as potential
biomarkers using this dataset. A Kaplan-Meier estimator was used to model survival
in both studies, separating patients by either clonality (greater or less than 0.1)
or number of expanded clones (greater or fewer than 100). Patients with diverse
baseline repertoires survived significantly longer (p < 0.05) than patients with clonal
repertoires when treated with anti-CTLA4. Likewise, for patients treated with anti-
CTLA4, patients who expanded more than 100 clones following treatment survived
significantly longer (p < 0.01, Figure 2.36, top). Understandably, neither of these
predictors were valid for patients treated on the anti-PD1 study (Figure 2.36, bottom).
48


































































































Figure 2.36: Kaplan-Meier survival analysis of patients
enrolled in the anti-CTLA4 (top) or anti-PD1 (bottom)
studies. Patients were divided into diverse or clonal
groups (left, using 0.1 as a clonality cutoff) or high and
low number of expanded clones (right, using 100 clones
as a cutoff).
To compare the TCR metrics to other, more easily attainable possible biomark-
ers, the same analysis was performed using absolute lymphocyte count at baseline
(greater or less than 1000), as well as the treatment arm. Patients with high base-
line lymphocyte count survived marginally longer (not significant) than lymphopenic
patients in both studies (Figure 2.37, left). Patient in combination therapy arms
(anti-CTLA4 + GVAX and anti-PD1 + GVAX + LM) survived slightly longer than
those in comparable arms (anti-CTLA4 only, or GVAX + LM only), but this trend
was not significant (Figure 2.37, right).
49































































































anti−PD1 + GVAX + LM
Figure 2.37: Kaplan-Meier survival analysis of patients
enrolled in the anti-CTLA4 (top) or anti-PD1 (bottom)
studies. Patients were divided into high or low absolute
lymphocyte count (left, using 1000 as a cutoff) or treat-
ment arm (right).
Because anti-PD1 acts at the site of the tumor, we next compared TCR repertoires
of pre-treatment tumor biopsies to post-therapy biopsies in a subset of patients. The
sample clonality is a valid representation of the total T-cell population unless the
sample size is very small. To assure that the clonalities used in the tumor analysis
were valid, any sample with fewer than 100 total TCR sequences was discarded. This
resulted in two pre-treatment biopsies and three post-treatment biopsies identified
as unusable for analysis (Figure 2.38). Unfortunately, the removal of these samples
left only one sample in the GVAX + LM arm with paired pre and post-treatment





































Figure 2.38: Total number of TCR sequences in tumor
biopsies from the anti-PD1 trial
Patients who received anti-PD1 had no significant differences in their baseline
repertoire clonality, and post-treatment clonality was incomparable due to low sample
sizes (Figure 2.39). Metrics comparing pre and post-treatment samples (change in
































Figure 2.39: The clonality of tumor samples from pa-
tients in the anti-PD1 trial, separated by time point and
treatment arm
After filtering, sufficient numbers of samples for comparisons between clinical re-
sponders and non-responders remained. No difference was observed between response
groups in the clonality at either time point (Figure 2.40). Likewise, no trend was ob-

































Figure 2.40: The clonality of tumor samples from pa-































Figure 2.41: The Log2 fold change in clonality of the tu-
mor repertoire, from patients in the anti-PD1 trial, sep-
arated by clinical response.
The Morisita index was unchanged between responders and non-responders (Fig-



















Figure 2.42: The Morisita index comparing pre and post-
treatment samples from patients on the anti-PD1 trial,
separated by clinical response
55
2.4 Discussion
This study represents the largest collection of TCR repertoire profiles from pancreatic
cancer trials to date. Repertoire features were found to vary with treatment arm, and
in some contexts, clinical response. These findings provide a platform for hypothesis
generation as well as a starting point for the development of novel biomarkers in a
disease which desperately needs them.
Analysis of the neoadjuvant and adjuvant GVAX trials demonstrated one of the
main challenges associated with cross study analyses: patient heterogeneity. Because
the baseline repertoire clonality was, on average, much lower in the neoadjuvant
study, comparisons between the two studies were difficult to make. This difference
in baseline characteristics is difficult to explain, as both studies recruited patients
without metastatic disease and no significant difference was observed between the
ages of the enrolled patients.
Patients treated with neoadjuvant GVAX experienced more changes in their reper-
toire following treatment than patients in the adjuvant trial. This could be a result of
GVAX-primed T-cells interacting with the tumor and expanding following treatment.
In the adjuvant study, the tumor is removed before vaccination, taking with it any
existing population of tumor infiltrating T-cells, but also a large source of antigen for
vaccine primed T-cells to attack.
Baseline differences also interfered with the ability to observe effects of cyclophos-
phamide on the T-cell repertoire. Because patients administered this drug had lower
baseline clonality than those receiving only neoadjuvant GVAX, these arms appear
to experience less diversification following treatment. This observation is likely an
artifact which occurs in patients with very diverse baseline repertoires who have very
little room for diversification following treatment.
The assay also failed to detect significant differences between clinical responders
and non-responders, which may have been due to the small sample size. A power
56
analysis of the baseline samples from the adjuvant GVAX trial, for example, revealed
that with the heterogeneity of the samples, the analysis only had 62% power to
identify a difference in clonality of 0.085 (the difference separating clinical responders
in the anti-CTLA4 study) with n = 5 samples per group. To achieve 80% power
(with α = 0.05), at least 8 samples per group would be necessary under the same
assumptions.
TCR repertoire samples from the SBRT study showed no measurable difference
between patients treated with GVAX and those only receiving SBRT and radiation.
This study provided the first indication that the effect of GVAX on the peripheral
repertoire is likely too small to be measured using these metrics. The study did
support the hypothesis that radiation can damage the peripheral repertoire, as a clear
correlation was observed between the change in clonality and the radiation volume,
with the trend suggesting that lower volumes of affected tissue correspond to larger
diversifications following treatment. It is worth noting that the magnitude of this
change is relatively small, as no large shifts are seen in the average clonality before
and after radiation treatment (Figure 2.19).
Finally, the immune checkpoint inhibitor trials demonstrated that the best appli-
cation of TCR sequencing is in the context of treatments which have large effects on
the peripheral repertoire. The anti-CTLA4 trial exhibited the largest bulk changes in
the repertoire (Figure 2.31), and suggests (though it did not reach statistical signifi-
cance) that the addition of GVAX may further enhance this change. GVAX is likely
providing a large source of antigen which can be presented to T-cells by APCs (signal
1), while anti-CTLA4 allows efficient costimulation (signal 2). This mechanism also
accounts for the extremely high number of expanded clones identified in a subset of
patients enrolled on this trial.
Both diverse baseline repertoires and high number of expanded clones were signif-
icantly associated with clinical response in the anti-CTLA4 trial. Other groups have
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demonstrated the potential of repertoire diversity as a biomarker for immunotherapy
efficacy20, but this is the first demonstration in pancreatic cancer.
The failure of these biomarkers in the context of anti-PD1 treatment is unsurpris-
ing, given that this treatment acts on tumor infiltrating lymphocytes. Other groups
have noted the differences in peripheral repertoire metrics between CTLA4 and PD1
blockade therapy22. Data from tumor samples was inconclusive due to the small
sample size after quality control filters were applied. The variance of clonality in
the tumor samples was actually lower than that of blood samples, indicating that if
the sample sizes had been larger, smaller changes in tumor clonality would be de-
tectable. Unfortunately, surgical resections and biopsies were often unattainable and
all available samples were used for this analysis.
The large numbers of samples used in the analysis of these four clinical trials
provide a robust measure of the distribution of repertoire clonality in patients with
pancreatic cancer (shown in Figure 2.43, left). Accurate description of this distribu-
tion allows a power analysis to be performed, approximating the number of samples
needed to detect a given change in clonality under various assumptions (Figure 2.43,
right).
This analysis of 343 TCR repertoire samples from 106 pancreatic cancer patients
enrolled in four immunotherapy clinical trials has provided a number of new insights
into the treatment of this disease, and the application of this technology. First, it
can be concluded that the effects of cancer vaccines are difficult to detect at the level
of the repertoire, while effects of immune remodelling therapies like anti-CTLA4 are
more obvious. Second, it is clear that the clonality and number of expanded clones
are important metrics in the analysis of TCR repertoire data from clinical samples.
Finally, it is clear that in certain clinical contexts, these metrics have the potential
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Figure 2.43: The distribution of the clonality from all pe-
ripheral repertoire samples used in this study (n = 265,
left). A parametric power analysis using three assump-
tions for the standard deviation, showing the number of
samples needed (vertical axis) to detect a given change in






The next generation of cancer vaccines will be tailored to the unique set of muta-
tions present in the tumors of each patient (the tumor mutome). Unlike GVAX and
other allogeneic vaccines, personalized vaccines will target only mutations known to
be present in the tumor, targets which will ideally be the result of a rational design
process to select tumor antigens most likely to lead to immunity. A variety of meth-
ods have been developed to formulate vaccines targeting specific antigens, including
genetic engineering of dendritic cells30 or Listeria monocytogenes12 to express tumor
antigens. The simplest approach, however, is to administer peptides encoding tumor
antigens directly. The peptides must be co-administered with an adjuvant to enhance
antigen uptake and presentation by APCs, and induce costimulatory molecules and
cytokines31. Peptide vaccines have been used successfully in preclinical models32,33,
but more recently they have been studied in human trials in head and neck34, breast35,
colorectal36, brain37 and even pancreatic cancer38 with varying degrees of success.
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These majority of peptide vaccine trials target point mutations, often commonly
occurring in their respective cancers, but other groups39 have recognized the potential
for targeting fusion peptides, which result from genomic rearrangements common in
many cancers. Fusion-derived antigens offer a number of advantages as potential
targets for peptide vaccines. Relative to point mutations, fusions generate more
exotic peptide sequences which may be more likely to be recognized as foreign by the
immune system. Chromosomal rearrangements frequently occur in introns (which
are, on average, much larger than exons), which results in fusion products generated
by exons from different genes which are spliced together. This results in patients with
a wide array of different genomic rearrangements expressing the same fusion protein.
The EML4-ALK fusion is present in a small subset of non-small cell lung cancer.
Around 15 variants of the fusion protein have been identified, but the three most
common make up 71% of the cases40. The p53 tumor suppressor gene, in contrast, is
mutated in around half of all cancers, but so many different mutations are possible
that the three most common mutations are present in only 18% of the total cases41.
Because of this disparity, vaccines derived from fusion antigens may be effective in a
greater percentage of the target population.
Peptide vaccination efforts have benefited greatly from the development of algo-
rithms capable of predicting peptide/MHC binding affinities. While not the entire
picture, peptide loading is one of the biological bottlenecks of antigen presentation,
and the ability to filter out vaccine candidates with little likelihood of presentation
has dramatically improved design efforts. Early efforts to predict this complex molec-
ular interaction were codified in the SYFPEITHI algorithm42, which built a large
database of known peptide/MHC affinities. More recently, an artificial neural net-
work, NetMHC has been trained on the initial data from the SYFPEITHI database,
augmented with other data sources43. The same group is developing tools to predict
immunoproteosomal processing44 and TCR recognition45.
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In this study, fusion proteins were identified and targeted in two preclinical murine
models of lung and colon cancer. Fusion identification was achieved using RNAseq
data, but validation efforts using whole genome sequencing showed that current algo-
rithms to identify these events from next-generation RNA sequencing data result in
unacceptably high false positive rates. The methods used to test immunogenicity of
candidate peptides were successful, and the peptide vaccination strategy succeeded in
a tumor prevention model. These successes demonstrate that with improved accuracy
of rearrangement finding methods, fusion-based peptide vaccines may provide clinical
benefit to patients with a variety of cancer types.
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3.2 Materials and Methods
3.2.1 Cell Lines and Mice
All mice used in this study were C57/BL6, aged 5-6 weeks, and were purchased from
Jackson Laboratories. Mice were treated in accordance with Institutional Animal
Care and Use Committee and American Association of Laboratory Animal Committee
approved policies.
We chose to use two well studied cell lines derived from the BL6 mouse, capable
of growth when injected subcutaneously. MC38 is a chemically induced colon adeno-
carcinoma cell line46, and Lewis Lung Carcinoma (LLC) is a lung carcinoma cell line
derived from a spontaneous tumor in a BL6 mouse47.
Both cell lines were maintained in DMEM with 10% Fetal Bovine Serum, 1%
Penicillin/Streptomycin and 1% L-Glutamine. Cells were passaged in a 10% CO2
incubator, and were washed with sterile PBS before injection.
3.2.2 Identification of Fusion Proteins
RNA was extracted from 5×106 cells of each cell line using the Qiagen RNeasy Kit.
Samples were sequenced using an Illumina HiSeq using the default paired-end protocol
for RNA-Seq. Reads were aligned to the mouse mm9 genome (accessed from the
UCSC Genome Browser48) using the bowtie aligner49. Fusions were identified using
the tophat-fusion algorithm50 with the settings listed in Table 3.1.
Option Name Value
Inner mate distance mate-std-dev 80
standard deviation
Maximum intron length max-intron-length 100000
Minimum fusion separation min-fusion-dist 100000
Minimum base pair mapping fusion-anchor-length 13
Table 3.1: Settings used for the tophat-fusion algo-
rithm
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Fusions identified with tophat-fusion were then manually curated by examining
the read mappings in the Integrated Genomics Viewer51 (IGV), Fusion events which
could not lead to a protein product (i.e. loss of start codons) were discarded.
A 20 base pair sequence with the fusion at the center was extracted for each candi-
date fusion. Binding of candidate fusion peptides to T2-Db and T2-Kb was predicted
computationally using the NetMHC 3.4 algorithm52 by submitting all possible 8, 9,
10 and 11mer peptides contained in the total 20mer.
3.2.3 Validation of Candidate Immunogenicity
Candidate 20-mer sequences were synthesized by Peptide 2.0, with a target purity of
95% and stored frozen in lyophilized form until use.
To test the immunogenicity of fusion peptides, 5-6 week old BL6 mice were vacci-
nated with either 50µg of each peptide in PBS with 10µg of Poly I:C as adjuvant, or
a control vaccine with the Ova peptide (GLEQLESINFEKLTEWTSS) and adjuvant.
A boost vaccine of the same formulation was administered 7 days after the initial
vaccine. On day 14, spleens were harvested and pooled by treatment group. Cell
suspensions were created by forcing spleens through a 40µm screen into CTL media
(RPMI, 10% FBS, 0.5% L-glutamine, 1% Penicillin/Streptomycin, and 0.05mM 2-
mercaptoethanol). Red blood cells were removed by lysis using Ammonium-Chloride-
Potassium (ACK) buffer. T cells were harvested by negative selection from whole
splenocytes using the Dynal CD8+ Negative Isolation kit.
Immunogenicity of the vaccine peptides was determined using an ELISpot assay.
T2-Db or T2-Kb cells were pulsed with 2µg/mL of each candidate peptide for 2 hours.
CD8+ T cells from treated mice were combined in equal parts with either pulsed T2-
Db or T2-Kb (105 of each) in triplicate wells of an anti-mouse-IFN-γ coated ELISpot
plate (mAb AN18, Mabtech). To address the possibility of CD4+ responses, as well as
any response not restricted to Db or Kb, 106 splenocytes were plated in triplicate with
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2µg/mL of each peptide. After 12-18 hours the cells were dumped off and the plate
was washed 6 times in PBS with 0.05% Tween. A biotinylated anti-IFN-γ secondary
antibody (mAb R4-6A2, Mabtech) was added at 10µg/mL for 2 hours, and the plate
was washed as before. An avidin-conjugated peroxidase (Vectastain ELITE ABS,
Vector Laboratories) was added and incubated for 1 hour. The plate was washed and
AEC substrate was added. The substrate was allowed to incubate for 15 minutes
before it was removed by rinsing in tap water. Plates were allowed to dry and IFN-γ
spots were counted using an ImmunoSpot analyzer.
3.2.4 Assessment of Anti-tumor Activity
Mice were vaccinated as described in Section 3.2.3, and on day 14 after initial treat-
ment, they were challenged with 105 tumor cells, injected subcutaneously into the
leg. Tumors were measured using calipers in two perpendicular directions and the
resulting measurements were averaged and reported as the average tumor diameter.
In tumor measurement studies, an additional vaccine group was treated using 3
peptides previously described to induce an anti-tumor response in the MC38 model53.
These peptides were derived from the Reps1 gene (VLELFRAAQLANDVVLQIME),




3.3.1 Identification of Fusion Proteins from RNAseq
In the MC38 cell line, 20,593,925 paired tags were aligned to the mouse mm9 genome by
bowtie. tophat-fusion Identified 14 putative fusions in this dataset, and inspection
using IGV identified 8 which could potentially yield a fusion protein product.
The Lewis Lung Carcinoma sample was similar, with 21,419,009 paired tags
aligned to the genome. Nineteen fusions were identified, with 9 potential, translatable
fusions found.


















Table 3.2: Candidate fusions identified by RNAseq, along
with an indication of which peptides had <500nM pre-
dicted affinity for MHC alleles.
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3.3.2 Validation of Candidate Immunogenicity
Using NetMHC, 4 peptides were identified as having at least moderate binding affinity
(<500nM) to H-2-Kb. The sequences, names used in this study, and NetMHC binders
are identified in Table 3.2.
To determine which peptides were capable of inducing an immune response, an
ELISpot assay was performed using CD8+ T cells from vaccinated mice as effector
cells and T2 cells expressing mouse MHC molecules (T2-Db or T2-Kb ) as antigen
presenting cells. Four peptides derived from LLC induced strong IFN-γ secretion
(LLC-6,10,16 and 19) when presented by T2-Kb . Two of these peptides (LLC-16 and
19) also induced some response when presented by T2-Db , which may be the result



































































































































































































Figure 3.1: IFN-γ ELISpot results from the LLC candi-
date fusions, using T2-Kb and T2-Db as antigen present-
ing cells. Ova, used as the positive control included in
the vaccine.
To address the possibility of antigen presentation by HLA-A2, the assay was
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repeated using T2 cells expressing neither mouse MHC molecule (but still expressing
HLA-A2). The T2 cell line was able to present LLC-16 and 19 using HLA-A2, however
dramatically fewer spots were seen, indicating that the peptides may be presented on




































































































































































































































Figure 3.2: IFN-γ ELISpot results from the LLC can-
didate fusions, using T2 cells as antigen presenting cells
(left) and splenocytes as a source of APC and effector
cells (right)
To determine if these peptides were capable of endogenous presentation, the
ELISpot assay was repeated using whole splenocytes from vaccinated mice to pro-
vide both the APCs and effector cells (CD8+ and CD4+ T cells). Interestingly, both
LLC-16 and LLC-19 induced strong IFN-γ responses when pulsed onto whole spleno-
cytes, however LLC-6 and 10 were undetectable (Figure 3.2). These peptides induced
only moderate responses in experiments using T2-Kb as antigen presenting cells, so
it is possible that the splenocyte assay was not sensitive enough to capture these
responses.
Eight fusion candidates were identified in the MC38 cell line, which were tested
using the same methods. ELISpot results, when using T2-Kb and T2-Db as APCs,
identified MC38-10 and MC38-13 immunogenic peptides (Figure 3.3), presented by
T2-Kb . Additionally, MC38-1 induced a small but reproducible IFN-γ response when
presented on T2-Db . Replication of this experiment confirmed the immunogenicity
68
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Figure 3.3: IFN-γ ELISpot results from the MC38 candi-
date fusions, using T2-Db and T2-Kb as antigen present-
ing cells
Of the 4 LLC immunogenic hits, only LLC-10 was predicted to bind H-2-Kb,
Interestingly, two peptides contained in the LLC-10 20mer were predicted to bind,
TAPDYFLL (predicted affinity 193nM) and the longer TAPDYFLLQV (349nM).
The LLC-18 peptide (YGAGYHMTL) was predicted to bind Kb with 284nM affinity,
however, it did not induce a response in IFN-γ ELISpot experiments.
Three LLC derived peptides were immunogenic in IFN-γ ELISpot assays, despite
poor binding predictions from NetMHC. The highest affinity peptide predicted from
LLC-6 was IKPEWLVKI, with a predicted affinity of 3923nM. LLC-16 and 19 were
even weaker binders, with best predicted affinities of 5325 and 14820nM, respectively.
MC38-derived peptides MC38-10 (GTFDRSVTL) and 13 (AVMGRTLSM) were
both predicted to bind to H-2-Kb (477nM and 325nM, respectively). Both of these
peptides induced an IFN-γ response in ELISpot assays.
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MC38-7, which was identified as immunogenic in ELISpot assays, had a weak
predicted affinity of 4837nM to Kb (peptide QSLSCCVCGGL). Interestingly, MC38-
1 was identified as immunogenic when presented by T2-Db , yet its best predicted
binder was IVVVGTGT, with a predicted affinity of 31694nM. This peptide was
actually predicted to bind to Kb with a higher affinity (7279nM), but no evidence was
seen for this in IFN-γ ELIspots.
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3.3.3 Assessment of Anti-tumor Activity
To assess the therapeutic potential of the fusion peptides identified, we performed
a preventative vaccine experiment in which all candidate fusions (regardless of im-
munogenicity) for each tumor were administered in two doses (prime and boost)
before tumor challenge. A vaccine containing the Ova peptide and adjuvant was used
as a negative control.
No difference in tumor size was observed between fusion peptide groups and the
negative control in either the LLC or MC38 models (Figure 3.4) when tumors were



































































Figure 3.4: Average tumor diameter of LLC tumors (left)
or MC38 tumors (right) when administered the fusion
vaccine (red) or a control vaccine (blue). Error bars rep-
resent mean ± SD.
To validate the vaccine administration method and timing, the preventative vac-
cine experiment was repeated with the addition of a positive control vaccine group.
This vaccine included peptides derived from point mutations identified in MC38,
which were shown to induce an anti-tumor immune response. The MC38 and LLC
fusion vaccines again demonstrated no anti-tumor effect, however the positive control
group significantly reduced tumor growth (Figure 3.5).
















































Figure 3.5: Average tumor diameters of mice treated with
fusion vaccines or control vaccines. Error bars represent
mean ± SD.
response in these mice, we confirmed that the immune response was still present 2
weeks after tumor challenge (3 weeks after the final vaccine dose) by performing an
IFN-γ ELISpot. Because the immune response is expected to be lower after 3 weeks,
an unchallenged cohort was included in this experiment.
In the LLC group, strong responses were seen against LLC-10, 16 and 19 at the
pre-challenged time point. These responses diminished 2 weeks later, however no
difference was seen between tumor challenged and unchallenged mice (Figure 3.6, top
panel, bottom row). A similar pattern was observed in mice treated with a control
vaccine (Figure 3.6, top panel, top row).
In the MC38 group, little reduction was seen in the number of IFN-γ spots at
the later time point in unchallenged mice (Figure 3.6, bottom panel, bottom row).
Tumor challenged mice exhibited a small reduction in the response, consistent with
a state of immune suppression. Interestingly, the control vaccine group exhibited a
72









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.6: IFN-γ ELISpot of vaccine treated mice before
tumor challenge (Pre-challenge), after 2 weeks without
challenge (Unchallenged) or 2 weeks after tumor chal-
lenge (Challenged). Top rows represent mice given a
control vaccine, bottom rows represent mice given the
respective fusion vaccines.
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3.3.4 Validation of Fusions using Whole Genome Sequencing
The lack of anti-tumor response from the fusion peptide vaccines could be caused by
candidate peptides not being expressed, processed or presented on MHC molecules.
To determine if the peptides identified in Section 3.3.1 using tophat-fusion were
truly present in the cell lines, we performed whole genome sequencing (WGS) on
genomic DNA from MC38 and LLC.
We identified putative fusion in the WGS data by identifying mate pairs which
aligned either to different chromosomes or to distant sites of the same chromosome.
Using permissive filters, we identified 1018 possible fusions in LLC and 262 in MC38.
Of the 1018 putative fusions from the WGS of the LLC cell line, only 2 overlapped
with the list of candidate fusions derived from RNAseq data in Section 3.3.1. LLC-11
was supported by 17 read pairs in the WGS data, and LLC-13 was supported by
only 4 pairs (LLC-13 was never tested in vivo because no translation was possible
from this fusion event). LLC-11 showed no immunological activity in IFN-γ ELISpot
assays.
Of the 262 candidates from WGS of the MC38 cell line, only 1 overlapped with
RNAseq hits. MC38-8 was supported by 12 read pairs in the WGS data, but showed
no biological activity in immune assays.
75
3.4 Discussion
Sequencing the transcriptome of the LLC and MC38 cell lines identified 17 putative
fusions which were targeted in a preventative cancer vaccine model. Eight of those
peptides induced a measurable immune response when administered with an adjuvant,
however, none of these candidates were able to protect mice from challenge with their
respective tumors. Immunization with previously validated peptides, known to be
expressed and presented by the MC38 cell line, demonstrated that the model used is
capable of detecting protective peptides. Finally, attempts to validate the candidate
fusions using WGS data failed to confirm the validity of any of the 8 immunogenic
peptides.
Algorithms like tophat-fusion are designed primarily for sensitivity (their ability
to detect fusions, in spite of the background noise associated with RNAseq data),
rather than specificity (the proportion of the candidates that are valid). In the context
of peptide vaccines, some lack of specificity is acceptable, as the inclusion of irrelevant
peptides (from invalid fusions identified in the data) does not, in theory, pose a risk
in terms of the safety or efficacy of the vaccine. The sensitivity of the algorithm in
our study is impossible to determine, as the true number of genomic rearrangements
is not known. The specificity can be estimated by examining the overlap between
hits obtained from RNAseq data and hits obtained from WGS. Unfortunately, this
estimate indicates a very low specificity, as a shockingly small number of RNAseq
hits had any evidence for validity in the WGS data. Because so few of the hits were
valid, the sensitivity was unacceptably high.
The experiment did succeed in demonstrating an efficient method for identifying
immunogenic fusions. Control vaccines also confirmed that immunogenic peptides,
in combination with adjuvant can reduce tumor growth in these preclinical models.
These in vivo and in vitro models are capable of identifying immunogenic and effective




Immunotherapy has shown great promise in a number of different cancer types, but
its benefits are often only seen by a subset of treated patients. This heterogeneity of
responses results from the fact that every patient has a truly unique immune system,
developed over a lifetime of antigen exposure. The two areas of research described
here represent parallel attempts to understand and overcome this problem. Profil-
ing of immune repertoires allows better understanding of what constitutes a healthy
immune system, while also predicting the likelihood of response to immunotherapy.
Personalized vaccines promise to deliver responses to more patients by assuring that
cases of rare mutations are not disadvantaged.
In Chapter 2, a large cohort of pancreatic cancer immunotherapy patients were
subjected to TCR repertoire profiling before and after treatment. The results of
this analysis have helped to build understanding about what effects are induced by
different forms of immune modulation. Anti-CTLA4 treatment appears to have the
largest effect on the T-cell compartment, while vaccination efforts, chemotherapy and
radiation are all much harder to measure. Efforts to extract meaningful data from
tumor infiltrating T-cell repertoires were hampered by low sample sizes, but statistical
evaluation of this data indicates that the quality of data from FFPE is no worse than
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that of peripheral cells, indicating that similar effect sizes are detectable from both
cell sources. The power analysis provided in Chapter 2.4 should be extremely useful
for the development of future experiments by helping to decide the number of samples
necessary to identify a desired effect size.
A model was developed to predict clinical response, and efforts to test this model
on new validation datasets will determine both its success in pancreatic cancer and
its applicability in other contexts. The model is built upon summary metrics of TCR
data, which only scratch the surface of available information created by this tech-
nology. HTTCS will find broader uses in cancer immunotherapy, especially in cases
where treatment involves the administration of known antigens (peptide vaccination
or similar) and cases of adoptive transfer of lymphocytes, where the input population
can be tracked.
Analysis of TCR data in the literature has been somewhat scattered in its ap-
proach and methodology. Early reports conflated the concepts of Richness (the num-
ber of unique TCRs identified) and diversity (which takes into account both Richness
and the distribution of clones within it). Richness was excluded from this analysis
early on because it was heavily correlated with the number of input cells sequenced.
The immunoSeqR package attempts to provide a framework for analyzing TCR reper-
toire data by combining the summary metrics and metadata aware functions to com-
pare and plot them.
Chapter 3 described attempts to develop a “personalized” vaccine targeting the
fusion proteins that arise as the result of genomic rearrangements in cancer. An ini-
tial RNAseq approach to identify candidate peptides failed to provide a significant
number of valid hits, rendering downstream efforts to characterize them unsuccessful.
The nature of modern sequencing technology amplifies the difficulty of detecting ge-
nomic rearrangements with high sensitivity and specificity. Current technologies rely
on sheared DNA libraries, which can confuse algorithms designed to detect natural
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fusions. New methods of library preparation, improvements to existing computational
methods, and use of newer sequencing chemistries capable of longer continuous reads
may help ameliorate the issue described above.
Both arms of this study have furthered our understanding of some of the largest
issues confronting cancer immunotherapy research. Continued efforts to develop se-
quencing based biomarkers using HTTCS will undoubtedly find successful niches.
Improved antigen identification efforts will facilitate the development of personalized
cancer vaccines to bridge the gap between responders and non-responders. Both ef-
forts will benefit greatly from research at the interface of biology and technology and
hopefully move forward into clinical settings to improve outcomes for cancer patients.
79
References
[1] N Howlader et al. SEER Cancer Statistics Review, 1975-2013. Sept. 2016.
[2] Audrey Vincent et al. “Pancreatic Cancer”. In: The Lancet 378.9791 (2011),
pp. 607–620.
[3] G. Bond-Smith et al. “Pancreatic Adenocarcinoma”. In: BMJ 344.may16 1
(May 2012), e2476–e2476.
[4] Matthew F. Krummel and James P. Allison. “CD28 and CTLA-4 Have Oppos-
ing Effects on the Response of T Cells to Stimulation”. In: Journal of Experi-
mental Medicine 182.2 (1995), pp. 459–466.
[5] D. R. Leach, M. F. Krummel, and J. P. Allison. “Enhancement of Antitumor
Immunity by CTLA-4 Blockade”. In: Science (New York, N.Y.) 271.5256 (Mar.
1996), pp. 1734–1736.
[6] Jennifer Couzin-Frankel. Cancer Immunotherapy. American Association for the
Advancement of Science, 2013.
[7] E. M. Jaffee et al. “Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating
Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety
and Immune Activation”. In: Journal of Clinical Oncology: Official Journal of
the American Society of Clinical Oncology 19.1 (Jan. 2001), pp. 145–156.
80
[8] E. R. Lutz et al. “A Lethally Irradiated Allogeneic Granulocyte-Macrophage
Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocar-
cinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation”. In: Annals
of Surgery 253.2 (Feb. 2011), pp. 328–335.
[9] Richard E. Royal et al. “Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-
4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma”. In: Journal
of immunotherapy 33.8 (2010), pp. 828–833.
[10] Dung T. Le et al. “Evaluation of Ipilimumab in Combination With Allogeneic
Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated
Pancreatic Cancer:” in: Journal of Immunotherapy 36.7 (Sept. 2013), pp. 382–
389.
[11] Kevin C. Soares et al. “PD-1/PD-L1 Blockade Together With Vaccine Therapy
Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors:” in: Journal of
Immunotherapy 38.1 (Jan. 2015), pp. 1–11.
[12] D. T. Le et al. “Safety and Survival With GVAX Pancreas Prime and Listeria
Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic
Pancreatic Cancer”. In: Journal of Clinical Oncology 33.12 (Apr. 2015), pp. 1325–
1333.
[13] B. Zink et al. “A Direct Estimate of the Human O4, T CeLL Receptor Diver-
sity”. In: (1999).
[14] Harlan S. Robins et al. “Comprehensive Assessment of T-Cell Receptor Beta-
Chain Diversity in Alphabeta T Cells”. In: Blood 114.19 (Nov. 2009), pp. 4099–
4107.
[15] D. Wu et al. “Detection of Minimal Residual Disease in B Lymphoblastic
Leukemia by High-Throughput Sequencing of IGH”. In: Clinical Cancer Re-
search 20.17 (Sept. 2014), pp. 4540–4548.
81
[16] William S. DeWitt et al. “Dynamics of the Cytotoxic T Cell Response to a
Model of Acute Viral Infection”. In: Journal of Virology 89.8 (Apr. 2015). Ed.
by R. M. Sandri-Goldin, pp. 4517–4526.
[17] Harlan Robins. “Immunosequencing: Applications of Immune Repertoire Deep
Sequencing”. In: Current opinion in immunology 25.5 (Oct. 2013), pp. 646–652.
[18] L. Robert et al. “CTLA4 Blockade Broadens the Peripheral T-Cell Receptor
Repertoire”. In: Clinical Cancer Research 20.9 (May 2014), pp. 2424–2432.
[19] E. Cha et al. “Improved Survival with T Cell Clonotype Stability After Anti-
CTLA-4 Treatment in Cancer Patients”. In: Science Translational Medicine
6.238 (May 2014), 238ra70–238ra70.
[20] Manuarii Manuel et al. “Lymphopenia Combined with Low TCR Diversity (Di-
vpenia) Predicts Poor Overall Survival in Metastatic Breast Cancer Patients”.
In: OncoImmunology 1.4 (July 2012), pp. 432–440.
[21] Michael A. Postow et al. “Peripheral T Cell Receptor Diversity Is Associ-
ated with Clinical Outcomes Following Ipilimumab Treatment in Metastatic
Melanoma”. In: Journal for Immunotherapy of Cancer 3 (2015), p. 23.
[22] Lidia Robert et al. “Distinct Immunological Mechanisms of CTLA-4 and PD-
1 Blockade Revealed by Analyzing TCR Usage in Blood Lymphocytes”. In:
OncoImmunology 3.6 (June 2014), e29244.
[23] E. R. Lutz et al. “Immunotherapy Converts Nonimmunogenic Pancreatic Tu-
mors into Immunogenic Foci of Immune Regulation”. In: Cancer Immunology
Research (June 2014).
[24] Ryan O Emerson et al. “High-Throughput Sequencing of T-Cell Receptors Re-
veals a Homogeneous Repertoire of Tumour-Infiltrating Lymphocytes in Ovar-
ian Cancer: Tumour-Restricted and Homogeneous TILs in Ovarian Cancer”. In:
The Journal of Pathology 231.4 (Dec. 2013), pp. 433–440.
82
[25] Marco Gerlinger et al. “Ultra-Deep T Cell Receptor Sequencing Reveals the
Complexity and Intratumour Heterogeneity of T Cell Clones in Renal Cell Car-
cinomas: Ultra-Deep Sequencing of T Cell Repertoires in Renal Cancer”. In:
The Journal of Pathology 231.4 (Dec. 2013), pp. 424–432.
[26] Paul C. Tumeh et al. “PD-1 Blockade Induces Responses by Inhibiting Adaptive
Immune Resistance”. In: Nature 515.7528 (Nov. 2014), pp. 568–571.
[27] C. E. Shannon. “A Mathematical Theory of Communication”. In: Bell System
Technical Journal 27.3 (July 1948), pp. 379–423.
[28] Yosef Hochberg and Yoav Benjamini. “More Powerful Procedures for Multiple
Significance Testing”. In: Statistics in medicine 9.7 (1990), pp. 811–818.
[29] Dung T. Le and Elizabeth M. Jaffee. “Harnessing Immune Responses in the
Tumor Microenvironment: All Signals Needed”. In: Clinical Cancer Research
19.22 (Nov. 2013), pp. 6061–6063.
[30] Wolfgang Walther, ed. Current Strategies in Cancer Gene Therapy. Vol. 209.
Recent Results in Cancer Research. Cham: Springer International Publishing,
2016.
[31] Hiep Khong and Willem W. Overwijk. “Adjuvants for Peptide-Based Cancer
Vaccines”. In: Journal for ImmunoTherapy of Cancer 4.1 (Dec. 2016).
[32] J. C. Castle et al. “Exploiting the Mutanome for Tumor Vaccination”. In: Can-
cer Research 72.5 (Mar. 2012), pp. 1081–1091.
[33] Madiha Derouazi et al. “Novel Cell-Penetrating Peptide-Based Vaccine Induces
Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity”. In: Cancer
Research (June 2015).
83
[34] Dan P. Zandberg et al. “A Phase I Dose Escalation Trial of MAGE-A3- and
HPV16-Specific Peptide Immunomodulatory Vaccines in Patients with Recur-
rent/Metastatic (RM) Squamous Cell Carcinoma of the Head and Neck (SC-
CHN)”. In: Cancer Immunology, Immunotherapy 64.3 (Mar. 2015), pp. 367–
379.
[35] Ryuji Takahashi et al. “Feasibility Study of Personalized Peptide Vaccination
for Metastatic Recurrent Triple-Negative Breast Cancer Patients”. In: Breast
Cancer Research 16.4 (2014), R70.
[36] S. Kibe et al. “Phase II Study of Personalized Peptide Vaccination for Previously
Treated Advanced Colorectal Cancer”. In: Cancer Immunology Research 2.12
(Dec. 2014), pp. 1154–1162.
[37] J. H. Sampson et al. “Immunologic Escape After Prolonged Progression-Free
Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccina-
tion in Patients With Newly Diagnosed Glioblastoma”. In: Journal of Clinical
Oncology 28.31 (Nov. 2010), pp. 4722–4729.
[38] M. K. Gjertsen et al. “Intradermal Ras Peptide Vaccination with Granulocyte-
Macrophage Colony-Stimulating Factor as Adjuvant: Clinical and Immunolog-
ical Responses in Patients with Pancreatic Adenocarcinoma”. In: International
Journal of Cancer. Journal International Du Cancer 92.3 (May 2001), pp. 441–
450.
[39] Monica Bocchia et al. “Complete Molecular Response in CML after P210 BCR–
ABL1-Derived Peptide Vaccination”. In: Nature Reviews Clinical Oncology 7.10
(Oct. 2010), pp. 600–603.
[40] Martin KH Maus et al. “Identification of Novel Variant of EML4-ALK Fusion
Gene in NSCLC: Potential Benefits of the RT-PCR Method”. In: International
journal of biomedical science: IJBS 8.1 (2012), p. 1.
84
[41] W. A. Freed-Pastor and C. Prives. “Mutant P53: One Name, Many Proteins”.
In: Genes & Development 26.12 (June 2012), pp. 1268–1286.
[42] H Rammensee et al. “SYFPEITHI: Database for MHC Ligands and Peptide
Motifs”. In: Immunogenetics 50.3-4 (Nov. 1999), pp. 213–219.
[43] Claus Lundegaard et al. “Major Histocompatibility Complex Class I Binding
Predictions as a Tool in Epitope Discovery: MHC Class I Binding Predictions”.
In: Immunology 130.3 (July 2010), pp. 309–318.
[44] Morten Nielsen et al. “The Role of the Proteasome in Generating Cytotoxic
T-Cell Epitopes: Insights Obtained from Improved Predictions of Proteasomal
Cleavage”. In: Immunogenetics 57.1-2 (Apr. 2005), pp. 33–41.
[45] Morten Nielsen et al. “Reliable Prediction of T-Cell Epitopes Using Neural Net-
works with Novel Sequence Representations”. In: Protein Science: A Publication
of the Protein Society 12.5 (May 2003), pp. 1007–1017.
[46] S. Rosenberg, P Spiess, and R Lafreniere. “A New Approach to the Adoptive
Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes”. In: Science
233.4770 (Sept. 1986), pp. 1318–1321.
[47] John S. Bertram and Przemyslaw Janik. “Establishment of a Cloned Line of
Lewis Lung Carcinoma Cells Adapted to Cell Culture”. In: Cancer Letters 11.1
(Nov. 1980), pp. 63–73.
[48] W. James Kent et al. “The Human Genome Browser at UCSC”. In: Genome
research 12.6 (2002), pp. 996–1006.
[49] Ben Langmead et al. “Ultrafast and Memory-Efficient Alignment of Short DNA
Sequences to the Human Genome”. In: Genome biology 10.3 (2009), R25.
[50] C. Trapnell, L. Pachter, and S. L. Salzberg. “TopHat: Discovering Splice Junc-
tions with RNA-Seq”. In: Bioinformatics 25.9 (May 2009), pp. 1105–1111.
85
[51] James T Robinson et al. “Integrative Genomics Viewer”. In: Nature Biotech-
nology 29.1 (Jan. 2011), pp. 24–26.
[52] S Buus et al. “Sensitive Quantitative Predictions of Peptide-MHC Binding by a
’Query by Committee’ Artificial Neural Network Approach”. In: Tissue antigens
62.5 (Nov. 2003), pp. 378–384.
[53] Mahesh Yadav et al. “Predicting Immunogenic Tumour Mutations by Com-




email: ahopkins@protonmail.com phone: (269)501-3602
Education The Johns Hopkins University School of Medicine 9/2013 - 8/2017 (Expected)
Candidate for Ph.D. in Cellular and Molecular Medicine
Massachusetts Institute of Technology 9/2006 - 6/2010
Bachelor of Science in Biology
Research
Experience
The Johns Hopkins University School of Medicine PhD Candidate
Laboratory of Elizabeth Jaffee, MD 9/2013 - Present
• Analyzed high throughput T-cell receptor β sequencing data to understand the mechanisms
of successful anti-tumor vaccination in pancreatic cancer
Developed an R package to compare samples in TCR sequencing experiments
Identified potential new biomarkers for pancreatic cancer immunotherapy
• Developed a novel preclinical cancer vaccine targeting immunogenic gene fusions
Identified unique gene fusions from RNAseq and Whole Genome Sequencing data
Developed and tested fusion vaccines in multiple murine cancer models
The Broad Institute of MIT and Harvard Research Associate I & II
Laboratory of Todd Golub, MD 9/2010 - 6/2013
• Worked in support of the Broad’s Cancer Cachexia and Hepatotoxicity projects in the
laboratory and as a computational analyst
• Assisted in development of methods for high throughput culture of human adipocytes,
myocytes and hepatocytes
• Performed genetic screen of secreted proteins in cancer cell lines, generated more than 9000
gene expression profiles and developed software to compare perturbed states to known gene
expression signatures, implicating a handful of putative cachexia-causing secreted proteins
• Developed software to analyze in-cell western blot data, including a graphical user interface
to increase usability for laboratory scientists
• Promoted to Research Associate II, November 2012
MIT Department of Biology Student Researcher
Laboratory of Michael Laub, PhD 1/2009 - 9/2010
• One of two winners of the John Asinari award for outstanding research in the field of life
sciences, 2010
• Worked with a graduate student to uncover the mechanisms of DNA damage in the model
organism Caulobacter crescentus
• Performed a large plasmid based synthetic lethal screen, discovered the function of a novel
gene, named sidA which causes a cell cycle arrest via a previously undescribed mechanism
Software
Development
immunoSeqR - An R package for analyzing high throughput T-cell receptor β sequencing data,
including metrics, metadata-aware plotting and single document reports. Available at
https://github.com/ahopki14/immunoSeqR
Hexis - A MATLAB GUI for comparing thousands of gene expression signatures to other known
signatures
icw - A MATLAB GUI for analyzing Licor in-cell western data
Publications and
Presentations
• T Cell Receptor Profiling in Pancreatic Cancer Patients Receiving Immune Checkpoint
Inhibition Combination Therapies. Alexander Hopkins, Mark Yarchoan, Jennifer N
Uram, Dung Le, Elizabeth M Jaffee and Eric R Lutz. (Manuscript in preparation)
• Relationship between lymphopenia and objective response rate with programmed death-1
(PD-1) inhibitor therapy: A single-center retrospective analysis. Mark Yarchoan, Adam
Diehl, Burles Avner Johnson III, Blake Scott, Alexander Hopkins, Nilofer Saba Azad,
Elizabeth M. Jaffee, Stuart A. Grossman. American Society of Clinical Oncology Abstract,
2017.
• Relationship of lymphocyte and eosinophil counts and immune-related adverse events in
recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective
analysis. Adam Diehl, Mark Yarchoan, Ting Yang, Blake Scott, Burles Avner Johnson
III, Alexander Hopkins, Nilofer Saba Azad, Elizabeth M. Jaffee, Stuart A. Grossman.
American Society of Clinical Oncology Abstract, 2017.
• Molecular Mediators of Cancer Cachexia. David Thomas, Alexander Hopkins, Nemanja
Marjanovic, Todd Golub. (Manuscript in preparation)
• Predicting Drug Toxicity using Multiplexed Gene Expression and High Content Imaging
in Primary Human Hepatocytes. David Thomas, Alexander Hopkins, Nemanja Mar-
janovic, Todd Golub. (Manuscript in preparation)
• Designing Diverse, High Content Assays to Uncover the Molecular Mediator of Cancer
Cachexia. Alexander Hopkins, David Rodriguez-Fuentes, David Thomas, Todd Golub.
Poster presented at the Broad Institute Scientific Retreat 2012
• Joshua Modell, Alexander Hopkins, Michael Laub. A DNA damage checkpoint in
Caulobacter crescentus inhibits cell division through a direct interaction with FtsW. Genes
Dev. 2011 Jun 15;25(12):1328-43.
Computer Skills • Experienced in analysis of data from T-cell receptor sequencing, gene expression, whole
genome sequencing, qPCR and survival experiments
• Skilled at using Linux, Mac OS, and Windows operating systems. Experienced with R,
MATLAB and Bash languages, as well as R Markdown, Sweave and LATEX document prepa-
ration systems
• Webmaster for Cellular and Molecular Medicine Graduate Program, Johns Hopkins Uni-
versity School of Medicine, 2013-Present
Laboratory Skills • Over seven years experience in mammalian cell culture, including human primary cells
• Experienced with a variety of model organisms, including bacteria, C. elegans and mice
• Familiar with a variety of molecular biology techniques
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